CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
VP4896drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00231946
NCT00231946Phase 3Completed
CompareCT.gov

A Double-Blind Placebo-Controlled Study of VP4896 For the Treatment of Mild-to-Moderate Alzheimer's Disease

Voyager Pharmaceutical Corporation·interventional·Posted Oct 4, 2005·Updated Sep 20, 2007

In Brief

A Phase 3 clinical trial evaluating VP4896 for Alzheimer's Disease. Completed, across 59 sites in 2 countries.

Detailed Summary

The study is designed to investigate the activity of the hormone drug leuprolide acetate in stabilizing cognitive function in mild-to-moderate AD patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 4, 2005
Enrollment StartSep 1, 2005
TodayJul 2, 2026
Posted 20.7 years ago

Interventions

VP4896drug